180 related articles for article (PubMed ID: 35793451)
1. Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant.
Jimenez Jimenez A; Komanduri K; Brown S; Wang T; Pereira D; Goodman M; Beitinjaneh A; Lekakis L; Chinapen S; Devlin S; Ponce D; Sauter C; Perales MA; Shaffer BC
Blood Adv; 2022 Aug; 6(15):4491-4500. PubMed ID: 35793451
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Antithymocyte Globulin-Post-Transplantation Cyclophosphamide-Cyclosporine-Based versus Antithymocyte Globulin-Based Prophylaxis for 10/10 HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.
Salas MQ; Alfaro-Moya T; Atenafu EG; Datt Law A; Lam W; Pasic I; Novitzky-Basso I; Santos Carreira A; Chen C; Michelis FV; Gerbitz A; Howard Lipton J; Kim DDH; Kumar R; Mattsson J; Viswabandya A
Transplant Cell Ther; 2024 May; 30(5):536.e1-536.e13. PubMed ID: 38281592
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bondarenko SN; Afanasyev BV
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1037-1042. PubMed ID: 26970381
[TBL] [Abstract][Full Text] [Related]
4. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343
[TBL] [Abstract][Full Text] [Related]
5. Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study.
Soltermann Y; Heim D; Medinger M; Baldomero H; Halter JP; Gerull S; Arranto C; Passweg JR; Kleber M
Ann Hematol; 2019 Jun; 98(6):1485-1493. PubMed ID: 30915500
[TBL] [Abstract][Full Text] [Related]
6. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
[TBL] [Abstract][Full Text] [Related]
7. The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation.
Dybko J; Sobczyk-Kruszelnicka M; Makuch S; Agrawal S; Dudek K; Giebel S; Gil L
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982839
[TBL] [Abstract][Full Text] [Related]
8. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation.
Battipaglia G; Labopin M; Kröger N; Vitek A; Afanasyev B; Hilgendorf I; Schetelig J; Ganser A; Blaise D; Itälä-Remes M; Passweg JR; Bonifazi F; Finke J; Ruggeri A; Nagler A; Mohty M
Blood; 2019 Sep; 134(11):892-899. PubMed ID: 31270102
[TBL] [Abstract][Full Text] [Related]
9. High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation.
Pedraza A; Jorge S; Suárez-Lledó M; Pereira A; Gutiérrez-García G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Transplant Cell Ther; 2021 Jul; 27(7):619.e1-619.e8. PubMed ID: 33895157
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia.
Dholaria B; Labopin M; Sanz J; Ruggeri A; Cornelissen J; Labussière-Wallet H; Blaise D; Forcade E; Chevallier P; Grassi A; Zubarovskaya L; Kuball J; Ceballos P; Ciceri F; Baron F; Savani BN; Nagler A; Mohty M
J Hematol Oncol; 2021 May; 14(1):76. PubMed ID: 33941226
[TBL] [Abstract][Full Text] [Related]
11. Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor.
Paviglianiti A; Ngoya M; Peña M; Boumendil A; Gülbas Z; Ciceri F; Bonifazi F; Russo D; Fegueux N; Stolzel F; Bulabois CE; Socié G; Forcade E; Solano C; Finel H; Robinson S; Glass B; Montoto S
Bone Marrow Transplant; 2024 May; 59(5):597-603. PubMed ID: 38331980
[TBL] [Abstract][Full Text] [Related]
12. Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donors.
Novitzky-Basso I; Remberger M; Chen C; Ellison C; Pasic I; Lam W; Law A; Gerbitz A; Viswabandya A; Lipton JH; Kim DD; Kumar R; Michelis FV; Mattsson J
Eur J Haematol; 2022 Apr; 108(4):288-297. PubMed ID: 34905239
[TBL] [Abstract][Full Text] [Related]
13. Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT.
Nagler A; Labopin M; Arat M; Reményi P; Koc Y; Blaise D; Angelucci E; Vydra J; Kulagin A; Socié G; Rovira M; Sica S; Aljurf M; Gülbas Z; Kröger N; Brissot E; Peric Z; Giebel S; Ciceri F; Mohty M
Cancer; 2022 Nov; 128(22):3959-3968. PubMed ID: 36110063
[TBL] [Abstract][Full Text] [Related]
14. Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation.
Mehta RS; Saliba RM; Rondon G; Al-Atrash G; Bashir Q; Hosing CM; Kebriaei P; Khouri I; Nieto Y; Oran B; Popat UR; Qazilbash MH; Ramdial J; Srour SA; Champlin RE; Rezvani K; Shpall EJ; Alousi AM
Transplant Cell Ther; 2022 Oct; 28(10):695.e1-695.e10. PubMed ID: 35902049
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
Brissot E; Labopin M; Labussière H; Fossard G; Chevallier P; Guillaume T; Yakoub-Agha I; Srour M; Bulabois CE; Huynh A; Chantepie S; Menard AL; Rubio MT; Ceballos P; Dulery R; Furst S; Malard F; Blaise D; Mohty M
Blood Cancer J; 2024 Feb; 14(1):31. PubMed ID: 38374026
[TBL] [Abstract][Full Text] [Related]
16. Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel S; Labopin M; Salmenniemi U; Socié G; Bondarenko S; Blaise D; Kröger N; Vydra J; Grassi A; Bonifazi F; Czerw T; Anagnostopoulos A; Lioure B; Ruggeri A; Savani B; Spyridonidis A; Sanz J; Peric Z; Nagler A; Ciceri F; Mohty M
Cancer; 2023 Dec; 129(23):3735-3745. PubMed ID: 37658621
[TBL] [Abstract][Full Text] [Related]
17. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.
Shaw BE; Jimenez-Jimenez AM; Burns LJ; Logan BR; Khimani F; Shaffer BC; Shah NN; Mussetter A; Tang XY; McCarty JM; Alavi A; Farhadfar N; Jamieson K; Hardy NM; Choe H; Ambinder RF; Anasetti C; Perales MA; Spellman SR; Howard A; Komanduri KV; Luznik L; Norkin M; Pidala JA; Ratanatharathorn V; Confer DL; Devine SM; Horowitz MM; Bolaños-Meade J
J Clin Oncol; 2021 Jun; 39(18):1971-1982. PubMed ID: 33905264
[TBL] [Abstract][Full Text] [Related]
18. Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation.
Chhabra S; Jerkins JH; Monahan K; Szabo A; Shah NN; Abedin S; Runaas L; Fenske TS; Pasquini MC; Shaw BE; Drobyski WR; Saber W; D'Souza A; Dhakal B; Mohan M; Longo W; Hamadani M
Bone Marrow Transplant; 2024 Mar; 59(3):373-379. PubMed ID: 38177221
[TBL] [Abstract][Full Text] [Related]
19. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
20. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
